Tagged with

IFPMA Eli Lilly and Company’s Melissa Barnes, who chairs the Ethics and Business Integrity Committee (eBIC) at the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA), and Thomas Cueni, the organisation’s director general, outline the key features of the IFPMA’s ambitious new Code of Practice and discuss the state of ethics…

Opinion After her son was diagnosed with SYNGAP1 – an extremely rare gene mutation – Monica founded Bridge the Gap – SYNGAP Education and Research Foundation to support families of those suffering from the illness and to accelerate the path to better therapies. Here Monica discusses the incredibly low rate of treatment options for…

Algeria Moncef Meklati, Merck’s general manager for North West Africa, discusses the company’s ambitions in the region, the key to successful joint ventures and evolving attitudes to chronic diseases in Algeria.   From the first day I started working for Merck, I’ve been impressed by the strong commitment of my team…

China Dr Michael Yu, founder, Chairman and CEO of Innovent Biologics, one of China’s most successful and innovative biopharma start-up, shares his long-term vision to build a company that can last a hundred years and more, Innovent’s mission to commercialize and develop affordable, high-quality biologics for ordinary people globally, and the…

France Nicolas Bardonnet of Promega France discusses the standout growth of the company on the occasion of its 40th anniversary, collaboration with France’s biotech clusters and the growth drivers of the future.   In France, we start to see hospitals coming to us, but also clinical diagnostic laboratories because for a…

Spain Sergio Serra Ripol, managing director of Tillotts Pharma Spain, highlights the challenges associated with setting up the affiliate and the strategic importance of Spain as Tillotts grows its European footprint. Furthermore, he gives an insight into the importance of relationships in building the company’s network and his vision for the…

China Rogier Janssens, GM of the Biopharma business of Merck KGaA, Darmstadt, Germany in China, shares the highlights of his first 16 months at the affiliate; the impact of the regulatory changes on the Biopharma business of Merck KGaA, Darmstadt, Germany in China; the significance of the affiliate’s commercial growth as…

Generics Over the last ten years, generic medicines have increased access to medicines by over 100% in 7 key therapeutic areas and have provided massive savings for healthcare systems in Europe. In this exclusive interview with Adrian van den Hoven, director general of Medicines for Europe, we discuss the importance of…

Bristol-Meyers Squibb Last week, Bristol-Myers Squibb (BMS) announced that they have entered into a definitive merger agreement under which Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 billion. Under the terms of the agreement, Celgene shareholders will receive 1.0 Bristol-Myers Squibb share…

UK Today NHS England have released their long-term plan to ensure the future of the NHS and the continued care of UK patients.   The plan is backed by 20.5 billion – the biggest funding settlement in NHS history. Informed by NHS staff and patients, the plan sets out their priorities…

Spain Melqui Calzado, general secretary of Catalonia Bio and Health Tech, highlights the association’s strategy to establish the region as an international reference centre for innovation and entrepreneurship, as well as giving an overview of the steps required to see a new wave of Catalan pharmaceutical companies.   Many large international…

Opinion Aditya Bhattacharji manages Eurasia Group‘s healthcare analysis. In this article, he gives his predictions for the political landscape in healthcare for 2019.  The challenges for firms are painfully apparent—there is bipartisan support in the US to lower drug prices, a pervasive sense that traditional advocacy methods are failing in today’s political climate,…